stars 1 stars 2 stars 3

Xilis, Inc. has ceased operations. This page is maintained so that people looking for Xilis can find where the technology went. The micro-organosphere (MOS) technology developed at Xilis is now commercially available from Uniform Bio as MOSgen, a benchtop instrument that lets a lab make MOS from its own samples. MOSgen uses microfluidics to turn one patient sample into 280,000 identical living 3D human models in fifteen minutes, for use in the plates, workflows, and instrumentation a lab already owns. It gives drug developers human biology at screening scale, so candidates can be de-risked early in discovery instead of in the clinic. If you arrived here from a publication or poster, the science stands as published. Keep citing the papers. For questions about the method, protocols, or running MOS in your own lab, contact Uniform Bio. If you had a project or partnership thread with Xilis, service work has ended and no new Xilis projects are being accepted. MOSgen puts the same technology on your bench. Commercial and partnering inquiries go to Uniform Bio. Follow Uniform Bio on LinkedIn: https://www.linkedin.com/company/uniformbio/ Website: https://www.uniformbio.com General inquiries: info@uniformbio.com Demo requests: demo@uniformbio.com MOSgen and MOS are for Research Use Only. MOSgen and MOS are trademarks of Uniform Bio, Inc.

xilis Questions

Gary Yeung is the Chief Financial Officer and President of Biopharma of xilis.

7 people are employed at xilis.

xilis is based in Durham, North Carolina.

Top xilis Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users